NCT05914857View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Prediabetic StateImpaired Fasting GlucoseImpaired Glucose Tolerance
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin Tablets, Oral, 10mg, Once daily

BEHAVIORAL

lifestyle interventions

Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

lead

Yangjin

OTHER